Dr. med. Piotr J.
Michel-Dziunycz

Medizinische Leitung

FMH Dermatologie und Venerologie

 
180213_Dermatologie-Zurich-Portrait-Fotos_A7R2-142-Edit-2.jpg
 

 
 

Ausbildung & Werdegang

Seit März 2018

Medizinische Leitung & Facharzt für Dermatologie & Venerologie
Schwerpunkt Dermatochirurgie

Dermatologie Klinik Zürich AG

 

2015 bis März 2018

Facharzt für Dermatologie & Venerologie
Dermis Hautklinik Bülach AG

 

2014

Fachexamen Dermatologie und Venerologie
Eidgenössisches Department des Inneren Bundesamt für Gesundheit

 

2010 bis 2014

Assistenzarzt Dermatologie und Venerologie mit speziellem Fokus auf Hautkrebs und Dermatochirurgie
Universitätsspital Zürich, Dermatologische Klinik

Dermatochirurgie-Praktikas zum Thema Mohs-Chirurgie
Harvard Medical School Boston, MA
Langone Medical Center, New York University, New York, NY

 

2008 bis 2010

Studienarzt Dermatoonkologie: Klinische Studien mit Krebspatienten
Universitätsspital Zürich, Dermatologische Klinik

 

2002 bis 2008

Studium Humanmedizin und Staatsexamen
Medizinische Universität Warschau und Universität Köln

Praktikas
ISREC Lausanne, Switzerland
Roswell Park Cancer Institute, Buffalo, NY
Pasteur Institute, Paris
BROAD Institute of Harvard and MIT, Boston MA

 
 

 
 

Sprachen

Deutsch, Englisch und Polnisch

 
 

 
 

Mitgliedschaften

ISDS: International Society for Dermatologic Surgery
FMH: Verbindung der Schweizer Ärzte
SGDV: Schweizerische Gesellschaft für Dermatologie und Venerologie
ESDR: European Society of Dermatological Research
SCOPE: Skin Care in Organ Transplant Patients Europe

 
 

 
 

Preise & Auszeichnungen

Academy of Future Leaders in Dermatology
Matching Funds Research Grant
SCOPE travel Fellowships
Young Investigator Award of the European Skin Research Foundation
René Touraine European Scholarship
Leonardo da Vinci Scholarship
French Governmental Research Scholarship
European Commission’s Scholarship

 
 

 
 

Publikationen

TLR4 as a negative regulator of keratinocyte proliferation.
Iotzova-Weiss G, Freiberger SN, Johansen P, Kamarachev J, Guenova E, Dziunycz PJ, Roux GA, Neu J, Hofbauer GFL.
PLoS One. 2017

 

miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS.
Neu J, Dziunycz PJ, Dzung A, Lefort K, Falke M, Denzler R, Freiberger SN, Iotzova-Weiss G, Kuzmanov A, Levesque MP, Dotto GP, Hofbauer GFL.
PLoS One. 2017

 

CYFIP1 is directly controlled by NOTCH1 and down-regulated in cutaneous squamous cell carcinoma.
Dziunycz PJ, Neu J, Lefort K, Djerbi N, Freiberger SN, Iotzova-Weiss G, French LE, Dotto GP, Hofbauer GF.
PLoS One. 2017

 

Considerable loss of information on skin cancer occurrence and non-adherence to clinical practice guideline in renal transplant recipients.
Leinweber N, Dziunycz PJ, French LE, Wüthrich R, Serra AL, Hofbauer GF.
J Eur Acad Dermatol Venereol. 2016

 

A Compression Kit of a Stocking and Three Superimposed Leggings Is Easy to Don and Dose Adjustable.
Luder C, Dziunycz P, Omid N, Radetzki AL, Lang C, Hübner M, Hafner J.
Eur J Vasc Endovasc Surg. 2016

 

Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.
Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF.
Mol Cancer Ther. 2015

 

S100A8/A9 stimulates keratinocyte proliferation in the development of squamous cell carcinoma of the skin via the receptor for advanced glycation-end products.
Iotzova-Weiss G, Dziunycz PJ, Freiberger SN, Läuchli S, Hafner J, Vogl T, French LE, Hofbauer GF.
PLoS One. 2015

 

Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells.
Håkerud M, Selbo PK, Waeckerle-Men Y, Contassot E, Dziunycz P, Kündig TM, Høgset A, Johansen P.
J Control Release. 2015

 

Multifactorial ERβ and NOTCH1 control of squamous differentiation and cancer.
Brooks YS, Ostano P, Jo SH, Dai J, Getsios S, Dziunycz P, Hofbauer GF, Cerveny K, Chiorino G, Lefort K, Dotto GP.
J Clin Invest. 2014

 

The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A.
Dziunycz PJ, Lefort K, Wu X, Freiberger SN, Neu J, Djerbi N, Iotzowa-Weiss G, French LE, Dotto GP, Hofbauer GFL.
J Invest Dermatol. 2014

 

EGFRvIII expression in squamous cell carcinoma of the skin.
Dziunycz PJ, Lazarova Z, Duncan N, Wong S, Neuburg M, Hofbauer GF, Olasz EB.
JAMA Dermatol.

 

Influence of cyclosporin and prednisolone on RAGE, S100A8/A9, and NFκB expression in human keratinocytes.
Djerbi N, Dziunycz PJ, Reinhardt D, Iotzova-Weiss G, Hafner J, Läuchli S, French LE, Hofbauer GF.
JAMA Dermatol. 2013

 

The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma.
Kanitz A, Imig J, Dziunycz PJ, Primorac A, Galgano A, Hofbauer GF, Gerber AP, Detmar M.
PLoS One. 2012;

 

Pronounced allelic imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients.
Mühleisen B, Petrov I, Frigerio S, Dziunycz P, French LE, Hofbauer GF.
Arch Dermatol. 2012

 

Organ transplantation and skin--principles and concepts.
Hofbauer GF, Freiberger SN, Iotzova-Weiss G, Shafaeddin B, Dziunycz PJ.
Curr Probl Dermatol.

 

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA.
J Clin Oncol. 2012

 

IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis.
Nobbe S, Dziunycz P, Mühleisen B, Bilsborough J, Dillon SR, French LE, Hofbauer GF.
Acta Derm Venereol. 2012

 

Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine.
Hofbauer GF, Attard NR, Harwood CA, McGregor JM, Dziunycz P, Iotzova-Weiss G, Straub G, Meyer R, Kamenisch Y, Berneburg M, French LE, Wüthrich RP, Karran P, Serra AL.
Am J Transplant. 2012

 

IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes.
Restivo G, Nguyen BC, Dziunycz P, Ristorcelli E, Ryan RJ, Özuysal ÖY, Di Piazza M, Radtke F, Dixon MJ, Hofbauer GF, Lefort K, Dotto GP.
EMBO J. 2011

 

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.
Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, Alonso C, Hofbauer GF, Boyle RW, Neri D.
Br J Cancer. 2011

 

Prevalence of Merkel cell polyomavirus among Swiss Merkel cell carcinoma patients.
Mangana J, Dziunycz P, Kerl K, Dummer R, Cozzio A.
Dermatology. 2010

 

Lichen sclerosus et atrophicus-like skin lesions in a patient carrying a novel hydroxymethylbilane synthase mutation.
Douderova D, Schneider-Yin X, Lautenschlager S, Saudek V, Theiler M, Hofbauer GF, Dziunycz PJ, Oyama N, French LE, Martasek P, Minder EI.
Blood Cells Mol Dis. 2010

 

Squamous cell carcinoma of the skin shows a distinct microRNA profile modulated by UV radiation.
Dziunycz P, Iotzova-Weiss G, Eloranta JJ, Läuchli S, Hafner J, French LE, Hofbauer GF.
J Invest Dermatol. 2010

 

Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas.
Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B, Ritter E, Gnjatic S, Kristiansen G, Moch H, Knuth A, Dummer R, van den Broek M.
Clin Cancer Res. 2010

 

Opposing roles for calcineurin and ATF3 in squamous skin cancer.
Wu X, Nguyen BC, Dziunycz P, Chang S, Brooks Y, Lefort K, Hofbauer GF, Dotto GP.
Nature. 2010

 

Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients.
Kosmidis M, Dziunycz P, Suárez-Fariñas M, Mühleisen B, Schärer L, Läuchli S, Hafner J, French LE, Schmidt-Weber C, Carucci JA, Hofbauer GF.
J Immunother. 2010

 

Immune phenotype of peripheral blood cells and skin squamous cell carcinoma in organ transplant recipients.
Dziunycz P, Hofbauer GF.
Expert Rev Clin Immunol. 2010

 

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Ribeiro U Jr, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M.
Nat Genet. 2009